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Abstract
Objective—Lipoprotein-associated phospholipase A2 (LpPLA2) activity was associated with 
higher CHD risk in a meta-analysis, which was partly dependent on circulating lipid levels. 
Apolipoprotein C3 loss-of-function (ApoC3 LOF) mutations were related with reduced 
postprandial lipemia and CHD risk. However, the association of LpPLA2 activity with ApoC3 
LOF is not known.
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Methods—We examined the association of LpPLA2 activity and ApoC3 LOF mutations and 
incident cardiovascular disease (CVD) (defined as coronary heart disease [CHD] plus ischemic 
stroke) and all-cause mortality in the biracial longitudinal Atherosclerosis Risk In Communities 
(ARIC) study.
Results—The mean LpPLA2 activity was 229.3 nmol/min/mL and was higher in men and 
whites. LpPLA2 activity correlated positively with atherogenic dyslipidemia. ApoC3 LOF carriers 
had lower LpPLA2 activity levels compared to non-carriers, and there was inverse association 
between LpPLA2 activity and ApoC3 LOF mutations in whites. In a fully adjusted model, greater 
LpPLA2 activity was independently associated with incident CVD (HR 1.35, 1.09–1.68 for 
highest vs. lowest quintile), which was mainly explained by its association with CHD, and was 
also associated with all-cause mortality (HR 1.65, 1.38–1.98).
Conclusions—Greater LpPLA2 activity was associated with increased CHD and all-cause 
mortality in both whites and African-Americans in the ARIC study. The inverse relation between 
LpPLA2 activity and ApoC3 LOF mutations suggests that delayed lipoprotein clearance may at 
least in part explain the observed association of LpPLA2 activity with increased CVD risk.
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Introduction
The concept that atherosclerosis is an inflammatory disease is supported by both the 
presence of inflammatory cells in the cap of atherosclerotic plaques and reports that elevated 
inflammatory markers in circulation are associated with increased incidence of coronary 
heart disease (CHD).1 The oxidative modification of low-density lipoproteins (LDL) within 
the arterial wall is a key early event in the development of atherosclerosis.2 It involves the 
oxidation of polyunsaturated fatty acid component of phospholipids and ultimately leads to 
the conversion of phosphatidylcholine (PtdCho) to lyso-PtdCho.3 The increased lyso-
PtdCho content of oxidized LDL is a chemoattractant for human monocytes and induces 
endothelial dysfunction.4,5 Lipoprotein-associated phospholipase A2 (LpPLA2) is a serine-
dependent lipase that has been shown to hydrolyze oxidatively modified PtdCho to release 
oxidized fatty acids and lyso-PtdCho.6 LpPLA2 is secreted by inflammatory cells in 
atherosclerotic plaques7 and is primarily responsible for the phospholipase activity 
associated with LDL.8 The expression of LpPLA2 is regulated by inflammatory mediators 
and inhibition of LpPLA2 activity results in decrease in both lyso-PtdCho content and 
monocyte chemoattractant ability of oxidized LDL.8,9 Recently the food and drug 
administration approved LpPLA2 activity to predict CHD risk.10
A meta-analysis by the LpPLA2 Studies Collaboration showed that higher LpPLA2 activity 
portends increased CHD risk but not ischemic stroke over a median of 6 years of follow-
up.11 However, the results from the individual studies included in the meta-analysis were 
not consistent. Furthermore, in subgroup analysis the association with CHD was significant 
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only in individuals with stable CHD, but not in those without history of CHD. Two large 
clinical trials designed to lower LpPLA2 activity using darapladip did not lower 
cardiovascular events in patients with established CHD.12,13 A recent study showed that 
variations in Phospholipase A2, Group VII gene (PLA2G7) that reduce LpPLA2 activity, did 
not have any effect on CHD risk.14
Apolipoprotein C3 (ApoC3) has been shown to inhibit the lipolytic activity of lipoprotein 
lipase and can promote delayed clearance of atherogenic lipoproteins.15 Furthermore, 
ApoC3 loss-of-function (LOF) variants are associated with lower triglycerides and small 
dense low-density lipoprotein cholesterol (sdLDL-C) levels and higher high-density 
lipoprotein cholesterol (HDL-C) levels, reduced postprandial lipemia and reduced CHD 
risk.16 Therefore, it is possible that individuals with ApoC3 LOF variants have lower plasma 
LpPLA2 activity levels due to lower levels of circulating atherogenic particles. In the 
Atherosclerosis Risk In Communities (ARIC) study, we previously studied the associations 
of LpPLA2 mass with CHD and ischemic stroke using a case cohort design.17,18 In the 
current study we investigated the relationship of LpPLA2 activity with ApoC3 LOF variants 




The ARIC study is a prospective epidemiologic study of 15,792 participants initially 
between 45 and 64 years of age from 4 U.S. communities started in 1987. Detailed 
information on the study design, objectives and sampling strategy has been previously 
described.19 ARIC cohort visit 4 conducted between 1996–1998, consisting of 11,656 
participants, served as the baseline for the present analysis. After excluding individuals with 
races other than African Americans or whites (n=31); African American participants from 
the Minnesota or Washington County field centers (n=37) (because their numbers were too 
small to provide good estimates for their race/center combinations); and 416 subjects 
without information on LpPLA2 and other covariates, a total of 11,172 participants aged 54 
to 74 years were available for our analysis. For each outcome of interest, individuals with 
prevalent disease were excluded. For example, with coronary heart disease (CHD) as an 
outcome, individuals with prevalent CHD were excluded, and with ischemic stroke as an 
outcome, individuals with prevalent ischemic stroke were excluded. Follow up time ended 
when the participant had an outcome, died, was lost to follow-up, or survived until 
December 31st 2009.
Covariates
Medical history, demographic data, anthropometric data, blood pressure measurements and 
fasting lipids were obtained during visit 4 following a standardized protocol. Participants 
were asked to fast for 12 hours before the clinic visit and 86% reported doing so. Diabetes 
was defined as fasting blood glucose level ≥126 mg/dL, non-fasting blood glucose level 
≥200 mg/dL, or self-reported physician diagnosis of or treatment for diabetes. Total 
cholesterol and high-density lipoprotein cholesterol (HDL-C) were determined by enzymatic 
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methods.20 Low-density lipoprotein cholesterol (LDL-C) was calculated using the 
Friedewald equation,21 small dense lipoprotein cholesterol (sdLDL-C) was measured using 
a novel homogeneous assay,22 and plasma apolipoproteins and high-sensitivity C-reactive 
protein were measured by immunonephelometric assay.22 Plasma LpPLA2 activity was 
measured in samples stored for approximately 10 years at −70°C using an automated 
Colorimetric Activity Method assay (diaDexus Inc., South San Francisco, CA) using a 
Beckman Coulter (Olympus) AU400e autoanalyzer. The LpPLA2 activity assay had an 
inter-assay variation coefficient of 4.4% and a reliability coefficient of 0.92, based on 419-
blinded replicate samples.
DNA sequencing was performed on Illumina HiSeqs (San Diego, CA) after exome capture 
with NimbleGen's VCRome2.1. Prior to statistical analysis, data were processed and alleles 
jointly called using Mercury.23
Many of the same ApoC3 variants reported previously were identified in our study. Three 
variants were identified in 23 carriers among white participants. These were 11:116701353 
(rs76353203, R19X, nonsense, 3 carriers), 11:116701354 (rs138326449, IVS2+1G->A, 
splice, 19 carriers) and 11:116701613 (rs140621530, IVS3+1G->T, splice, 1 carrier). Two 
of these three variants (11:116701353 and 11:116701613) were validated through 
genotyping from the exome chip array and exhibited 100% concordance with the 
overlapping ARIC participant's exome sequence variant. The 4 variants identified in 11 
carriers in African-American participants were 11:116701353 (rs76353203, R19X, 
nonsense, 2 carriers), 11:116701354 (rs138326449, IVS2+1G->A, splice, 3 carriers), 
11:116701613 (rs140621530, IVS3+1G->T, splice, 5 carriers) and 11:116703578 
(frameshift CA->C, 1 carrier). Two of these four variants (11:116701353 and 
11:116701613) were validated through genotyping from the exome chip array and exhibited 
100% concordance with the corresponding ARIC participant's exome sequence variant.
Outcomes
Stroke and CHD events were identified from continuous, comprehensive surveillance for all 
cardiovascular disease (CVD)-related hospitalizations and deaths in the 4 communities, and 
adjudicated on the basis of published criteria.24–28 For this study CVD was defined as CHD 
plus hospitalized ischemic stroke. CHD was defined as the occurrence of definite or 
probable myocardial infarction, definite fatal CHD, or a coronary revascularization 
procedure. The definition of definite myocardial infarction required that all following 3 
criteria be met; clinical history of new ischemic type chest pain, a new ischemic changes in 
electrocardiogram and a rise and fall in serum cardiac biomarkers. If only two of the three 
criteria were met the event was defined as probable MI. Stroke was defined as sudden or 
rapid onset of neurological symptoms that lasted for 24 hours or led to death in the absence 
of another cause.24,25,27 Qualifying strokes were further classified into definite or probable 
hospitalized ischemic stroke (neuroimaging showed acute infarction or no hemorrhage) or 
hemorrhagic stroke on the basis of neuroimaging studies or autopsy, when available. 
Patients with transient ischemic attacks were not included in the definition of ischemic 
stroke.
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We examined the distribution of ARIC visit 4 vascular risk factors across LpPLA2 activity 
quintiles and calculated linear correlations between LpPLA2 activity and traditional risk 
factors in the overall population and by gender and race categories, using Pearson’s 
correlation coefficients, except for triglycerides and high-sensitivity C-reactive protein for 
which we used Spearman’s rank correlations. A p value for trend was calculated by the 
Wilcoxon score rank sum test for continuous variables and by the Cochrane-Armitage trend 
test for categorical variables. Using Cox proportional hazards regression models, we 
calculated hazard ratios (HR) for CVD, CHD, ischemic stroke and total mortality by 
quintiles of LpPLA2 activity with the lowest quintile as the reference using various 
adjustment models (model 1: age, gender and race; model 2: model 1 + current smoking, 
systolic blood pressure, antihypertensive medication use, diabetes, log high-sensitivity C-
reactive protein; model 3: model 2 + HDL-C; model 4: model 2 + LDL-C; and model 5: 
model 2 + HDL-C + LDL-C). In a fully adjusted model (model 5), we also calculated the 
HR per 1-standard deviation (SD) increase in LpPLA2 activity for CVD, CHD, ischemic 
stroke and total mortality. The proportional hazard assumption was confirmed using time-
dependent covariates and likelihood ratio tests. Finally, to analyze the incremental value of 
LpPLA2 activity in risk prediction, areas under the receiver operating characteristic curve, 
net reclassification improvement and integrated discrimination improvement were 
calculated. Bootstrapping was performed to furnish 90% confidence intervals (CIs) for the 
differences between models. The basic models were without LpPLA2 activity; the extended 
models included LpPLA2 activity as quintiles.
In sensitivity analyses, the interactions of gender (men or women), race (whites or African 
American) and LDL-C (<2.59 or ≥ 2.59 mmol/L) each for the associations of LpPLA2 
activity with CVD, CHD, ischemic stroke and total mortality were assessed using the Wald 
chi-square test followed by subgroup analyses. We also examined the associations of 
LpPLA2 activity with individual CHD end points (definite or probable myocardial 
infarction, coronary revascularization and fatal CHD). Individuals with prevalent CHD were 
excluded for these analyses.
For genetic analysis of ApoC3 LOF variants, a gene-based test restricted on minor allele 
frequency less than 0.05 and missense, stop gain, and splice annotated variants was used.29
Analyses were performed using SAS version 9.3 (Cary, NC). All tests presented are two-
tailed, and a p-value <0.05 was considered statistically significant. The authors are solely 
responsible for the design, conduct and analyses of the study, and the drafting, editing and 
preparation of the final version of the manuscript. Research protocols were approved by 
each ARIC field center’s institutional review board and all participants provided written 
informed consent.
Results
LpPLA2 activity and risk factors
The mean age was 63 years (56% women, 22% African-Americans). Across increasing 
LpPLA2 activity quintiles, there were fewer African-Americans, women and hypertensive 
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participants, and lower levels of HDL-C and high-sensitivity C-reactive protein; and more 
smokers and higher levels of total cholesterol, LDL-C, apolipoprotein B (ApoB), 
triglycerides, and total cholesterol/HDL-C ratio (p for trend <0.0001 for all, table 1).
The mean (SD) LpPLA2 activity was 229.3 (62.3) nmol/min/mL overall and was 
significantly higher in men than women (261.4 vs. 203.9 nmol/min/mL, p<0.0001) and in 
whites than African-Americans (238.4 vs. 197.0 nmol/min/mL, p<0.0001). The mean (SD) 
LpPLA2 activity were 270 (53.5), 221 (54.8), 210 (53.4) and 182.1 (51.6) nmol/min/mL in 
white men, African-American men, white women and African-American women, 
respectively. The mean LpPLA2 activity was higher in incident CVD cases than non-cases 
(247.3 vs. 224.1 nmol/min/mL, p<0.0001), and also higher in incident CHD cases than non-
cases (252.0 vs. 224.2 nmol/min/mL, p<0.0001), but there was no significant difference in 
LpPLA2 activity levels between incident ischemic stroke cases than non-cases (233.1 vs. 
229.0 nmol/min/mL, p=0.168).
Plasma LpPLA2 activity was positively correlated with total cholesterol, LDL-C, ApoB, 
sdLDL-C, total cholesterol/HDL-C ratio and triglycerides with respective correlation 
coefficients (r) of 0.16, 0.37, 0.39, 0.32, 0.54 and 0.15; and was inversely correlated with 
HDL-C and high-sensitivity C-reactive protein with respective r of −0.50 and −0.13 (table 
2). In general, the correlations were numerically stronger with both HDL-C and atherogenic 
lipoproteins (e.g., LDL-C and ApoB) in women than men; and relatively weaker with HDL-
C, and relatively stronger with atherogenic lipoproteins in African-Americans than whites.
LpPLA2 and cardiovascular outcomes
Over a median of 11.9 years of follow-up there were 1,653 incident CVD; 1,373 CHD; 462 
ischemic stroke cases; and 2,185 deaths with incidence rates of 15.0, 12.3, 3.9 and 17.2 per 
1000 person-years, respectively. When adjusted for age, gender and race (model 1, table 3) 
the HR (95% CI) for CVD was 1.84 (1.53–2.20) in the highest vs. lowest LpPLA2 activity 
quintiles. The strength of association was similar when the model was further adjusted for 
smoking, systolic blood pressure, antihypertensive medication use, diabetes and high-
sensitivity C-reactive protein (1.90, 1.58–2.29) (model 2). The HRs attenuated when further 
adjusted for HDL-C (1.65, 1.35–2.01) (model 3) or LDL-C (1.58, 1.29–1.93) (model 4). In a 
fully adjusted model (model 5), there was further attenuation in the quintile 5 vs.1 HRs 
(1.35, 1.05–1.68). There was a significant trend for increasing CVD events with higher 
LpPLA2 activity levels in all models. When CHD and ischemic stroke were considered 
separately, associations appeared strong for CHD but largely null for ischemic stroke. 
Individuals with the highest LpPLA2 activity quintile were significantly more likely to have 
CHD than those with the lowest LpPLA2 activity quintile in the fully adjusted model (HR 
1.47, 95% CI 1.16–1.88), and there was a significant trend for increasing incident CHD 
events with higher plasma LpPLA2 activity quintiles (table 3). In addition, individuals with 
the highest LpPLA2 activity quintile had 65% greater risk of death compared to those with 
the lowest quintile (HR 1.65, 95% CI 1.38–1.98) in fully adjusted model. The associations 
for all-cause mortality became stronger when lipoprotein variables were adjusted for in 
addition to other vascular risk factors/markers (model 5), with significant trends for higher 
mortality risk with increasing LpPLA2 activity in most models. In separate analyses, the 
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HRs (95% CI) for CVD, CHD, ischemic stroke and total mortality per 1-SD higher LpPLA2 
activity (62.3 nmol/min/mL) using the fully adjusted model (model 5) were 1.14 (1.07–
1.21), 1.17 (1.10–1.24), 1.09 (0.96–1.23) and 1.16 (1.10–1.22) respectively.
Since LpPLA2 activity was significantly associated only with CHD and total mortality and 
not ischemic stroke, we compared the ability of models to predict risk only for CHD and 
total mortality. Adding LpPLA2 activity to model 5 resulted in significant but small 
improvements in areas under the receiver operating characteristic curve and integrated 
discrimination improvement for prediction of CHD and total mortality; the change in net 
reclassification improvement was not statistically significant (table 4).
Sensitivity analyses
There was no significant interaction by gender, race or LDL-C for the association of 
LpPLA2 activity with CVD, CHD, ischemic stroke or total mortality (p-interaction >0.05 for 
all analyses), except for significant interaction by gender for total mortality (p-interaction 
0.006). In subgroup analyses, the associations of LpPLA2 activity were numerically stronger 
for CVD and CHD in individuals with LDLC ≥2.59 mmol/L than with <2.59 mmol/L (table 
SI). The associations of LpPLA2 activity with CHD seemed to be numerically stronger in 
women than men and also in whites than African-Americans (tables SII–III). Similarly, risk 
for all-cause mortality seemed to be numerically higher in women than men (table SII), and 
also in African-Americans than whites (table SIII).
The results for individual coronary endpoints were in general similar to the overall CHD 
endpoint except that there was no linear trend for fatal CHD with increasing LpPLA2 
activity (table SIV).
LpPLA2 activity and ApoC3 LOF mutations
Considering the previously described inhibitive action of ApoC3 on lipoprotein lipase 
activity15 and it’s purported role in the delayed clearance of pro-atherogenic ApoB-
containing lipoproteins in individuals with atherogenic dyslipidemia,16 we investigated the 
relationship of LpPLA2 activity with lipids in non-carriers and carriers of ApoC3 LOF 
variants in whites and African-Americans. In white participants from the ARIC sample who 
had undergone exome sequencing (N=4,524) there were 23 individuals who were 
heterozygote carriers of ApoC3 LOF variants. There were no homozygous individuals. 
Combining the 3 rare LOF variants identified at the gene level, the association between 
LpPLA2 activity (as a continuous variable) and ApoC3 LOF mutations was significant in 
whites (beta = −32.95, SE=11.13, p=0.003). The association was similar with 1-SD increase 
in LpPLA2 activity (beta = −0.54, SE=0.18, p=0.003). For African-Americans with exome 
sequence data (N=1,802), 4 rare ApoC3 LOF variants were identified among 11 carriers. 
Although there was similar direction of association between LpPLA2 and ApoC3 LOF 
mutations in African-Americans, the association was not statistically significant (beta = 
−2.41, SE=15.49, p=0.88 when LpPLA2 activity was a continuous variable; beta = −0.16, 
SE=0.30, p=0.60 with 1-SD increase in LpPLA2 activity). In whites, compared to ApoC3 
LOF non-carriers those heterozygotes for ApoC3 LOF had lower levels of LpPLA2 activity 
(238.5 vs. 214.7 nmol/mL/min, p=0.04), triglycerides and sdLDL-C, and higher levels of 
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HDL-C (Table 5). Similarly in African-Americans, compared to non-carriers, carriers of 
ApoC3 LOF mutations had lower triglycerides and sdLDL-C levels and higher HDL-C 
levels, but there was no significant difference in LpPLA2 activity between non-carriers and 
carriers (195.6 vs. 188.4 nmol/mL/min, p=0.57).
Discussion
We found that plasma LpPLA2 activity was independently associated with incident CVD, 
which was mostly explained by its association with CHD and not ischemic stroke. 
Furthermore, greater LpPLA2 activity was associated with higher total mortality, especially 
in women. In whites, we found significant inverse association between LpPLA2 activity and 
ApoC3 LOF variants. Plasma LpPLA2 activity was lower in ApoC3 LOF carriers compared 
to non-carriers, but this was not seen in African-Americans. Although this could reflect 
fewer African-Americans in our study, it could also be related to gender differences in 
metabolism of postprandial lipemia and remnants even in those with ApoC3 LOF. Similar to 
recent reports,30 we also found that there were lower levels of triglycerides and sdLDL-C 
and higher HDL-C levels in ApoC3 carriers than non-carriers in both whites and African-
Americans, but there was no consistent differences seen in the levels of ApoB containing 
lipoproteins between ApoC3 carriers and non-carriers.
The food and drug administration recently approved LpPLA2 activity for CHD risk 
prediction.10 The approval was based on a validation study using data from the Reasons for 
Geographic And Racial Differences in Stroke study, which showed that patients with 
LpPLA2 activity levels ≥225 nm/min/ml were at higher risk for CHD than those with lower 
levels. Furthermore, African-American women with higher LpPLA2 activity levels were 
found to have the highest CHD risk. One of the novel findings of our study was the 
difference in LpPLA2 activity by race and gender. Therefore, race and gender specific 
diagnostic cutoffs of LpPLA2 activity may be more relevant.
Using individual level data from persons with and without history of CHD, the meta-
analysis by the LpPLA2 Studies Collaboration showed that with 1-SD increase in LpPLA2 
activity there was a significantly increased CHD risk (relative risk, RR 1.10, 95% CI 1.05–
1.16), but not significantly for ischemic stroke (RR 1.08, 0.97–1.20).11 This is consistent 
with our current findings. Lack of association of LpPLA2 activity with ischemic stroke 
could be due to low statistical power and other important pathophysiological mechanisms 
related to stroke, primarily hypertension. The risk for CHD was significant only in 
individuals with history of stable CHD in the meta-analysis, while there was no significant 
association in those without history of CHD.11 The present analysis included only 
individuals without a history of clinical CHD and showed significant positive association 
with incident CHD and individual CHD end points. Furthermore, we also showed 
associations in both men and women, and whites and African-Americans.
Prior studies have shown that LpPLA2 activity was strongly associated with single 
nucleotide polymorphisms for genes involved in lipid metabolism.31,32 We found that 
LpPLA2 activity had positive correlations with LDL-C, ApoB and sdLDL-C and a negative 
correlation with HDL-C, although these correlations were generally weak (r<|0.60|). As 
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previously reported we found that ApoC3 LOF mutations were associated with lower 
triglycerides and higher HDL-C levels.30,33 Furthermore, LpPLA2 activity and sdLDL-C 
levels were significantly reduced in ApoC3 LOF carriers compared to non-carriers. ApoC3 
inhibits the lipolytic activity of lipoprotein lipase and is also implicated in the delayed 
clearance of atherogenic cholesterol-rich remnants of the postprandial metabolism of 
triglyceride-rich lipoproteins.15,34 This is of particular importance since the delayed 
clearance of atherogenic lipoproteins leads to elevated levels of sdLDL-C, which have been 
shown to be highly enriched with LpPLA2.35 Taken together, these findings suggest that 
delayed clearance of atherogenic lipoproteins may at least in part explain the observed 
association of LpPLA2 activity with increased cardiovascular risk.
The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy 
(STABILITY) trial showed that LpPLA2 activity lowering using darapladip in patients with 
stable CHD did not reduce the occurrence of its primary endpoint.12 Similarly, the 
Stabilization of Plaques using Darapladib (SOLID-TIMI 52) trial failed to show a difference 
in major coronary events by lowering LpPLA2 activity using darapladip within 30 days of 
acute coronary syndrome.13 Consistent with these findings, a recent genetic study did not 
show reduced CHD risk in individuals with variation in PLA2G7 gene that is associated with 
reduction in LpPLA2 activity.14 Although we found a significant positive association 
between LpPLA2 activity and total mortality in the current study, no benefit of LpPLA2 
activity lowering was seen for total mortality in the STABILITY and SOLID-TIMI 52 
trials.12,13 It should be noted that the baseline median LDL-C was 2.07 mmol/L in the 
STABILITY trial (1.94 mmol/L in SOLID-TIMI 52 trial) and approximately 97% of 
patients were taking statin in each of the placebo and darapladip arm in the STABILITY 
trial (94% in SOLID-TIMI 52 trial). In our study, about 11.5% of the participants were using 
statin at baseline. Statins not only reduce atherogenic lipoproteins36 but can also reduce 
LpPLA2 activity.37–40 Another possible reason for the differences in the findings between 
the clinical trials and the current observational data is the shorter follow up in the clinical 
trials compared to that in the ARIC study. In addition, participants in the STABILITY and 
SOLID-TIMI 52 trials had stable CHD and acute coronary syndrome respectively and our 
current study was in individuals free of clinical CHD at baseline. However, a more likely 
explanation of the discrepancy between the epidemiological and the clinical trials data may 
largely be explained by increased concentration or delayed clearance of ApoB containing 
lipoproteins, which are in the causal pathway for atherosclerotic CVD and not the LpPLA2 
enzyme itself. Therefore, we postulate that risk reduction in individuals with elevated 
LpPLA2 activity would be to enhance clearance and reduce levels of atherogenic ApoB 
containing lipoproteins.
Our study has several strengths and weaknesses. Our findings were based on a well-
characterized large biracial population-based cohort followed for a median of 11.9 years. To 
our knowledge, this is the largest single study to date assessing the associations of LpPLA2 
activity in individuals without baseline CHD or ischemic stroke. All incident cardiovascular 
events were identified through an ongoing rigorous comprehensive surveillance process and 
adjudicated by a panel of standardized physician reviewers. Unfortunately, we did not have 
information on LpPLA2 activity associated with different lipoprotein fractions, as well as 
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plasma ApoC3 levels. Despite adjusting for multiple variables, it is possible that residual 
confounding might explain the observed associations. Finally, our study should only be 
considered as hypothesis generating.
Conclusions
In the present study higher LpPLA2 activity was associated with a significantly increased 
risk for incident CHD and total mortality. The inverse relation between LpPLA2 activity and 
ApoC3 LOF variants suggests that delayed clearance of atherogenic lipoproteins may partly 
explain the observed association of LpPLA2 activity with increased risk of CHD, which 
should be confirmed in future studies.
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Abbreviations
ApoB Apolipoprotein B
ApoC3 LOF Apolipoprotein C3 loss-of-function
ARIC Atherosclerosis Risk In Communities
CHD coronary heart disease
CVD cardiovascular disease
HDL-C high-density lipoprotein cholesterol
LDL(C) low-density lipoprotein (cholesterol)
LpPLA2 lipoprotein-associated phospholipase A2
PLA2G7 Phospholipase A2, Group VII (Platelet-Activating Factor 
Acetylhydrolase, Plasma)
PtdCho phosphatidylcholine
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sdLDL-C small dense low-density lipoprotein cholesterol
SOLID-TIMI 52 the Stabilization of Plaques using Darapladib
STABILITY the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib 
Therapy
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Table 5
Association of apolipoprotein C3 loss-of-function carrier state with circulating lipids
Whites
Lipids ApoC3 LOF genotype [N] P-value
Non-carriers [4501] Carriers [23]
LDL-C (mmol/L) 3.18±0.83 2.89±0.63 0.0362
Apolipoprotein B (g/L) 1.01±0.23 0.86±1.67 0.0004
sdLDL-C (g/L) 0.46±0.21 0.29±0.12 0.0001
HDL-C (mmol/L) 1.27±0.42 1.73±0.47 0.0001
Total cholesterol (mmol/L) 5.22±0.92 4.99±0.86 0.202
Total cholesterol/HDL-C ratio 4.49±1.46 3.00±0.64 0.0001
Triglycerides (mmol/L) 1.72±0.99 0.81±0.27 0.0001
LpPLA2 activity (nmol/mL/min) 238.5±60.8 214.7±53.4 0.04
African-Americans Lipids ApoC3 LOF genotype [N] P-value
Non-carriers [1791] Carriers [11]
LDL-C (mmol/L) 3.18±0.90 3.22±0.57 0.83
Apolipoprotein B (g/L) 0.95±0.24 0.89±0.23 0.49
sdLDL-C (g/L) 0.37±0.17 0.25±0.11 0.009
HDL-C (mmol/L) 1.38±0.44 1.56±0.25 0.04
Total cholesterol (mmol/L) 5.15±0.97 5.05±0.54 0.59
Total cholesterol/HDL-C ratio 4.02±1.29 3.32±0.67 0.007
Triglycerides (mmol/L) 1.30±0.75 0.60±0.24 0.0001
LpPLA2 activity (nmol/mL/min) 195.60±1.30 188.40±12.20 0.57
Data expressed as mean (standard deviation) and analyzed using R seqmeta package.
P-values were calculated with t test using Cochran test and unequal variance.
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